07-742 phase I/ feasibility study of short term fondaparinux [fondaparinux sodium] (Arixtra) in chemotherapy-pretreated ovarian carcinoma patients at high risk of progression.
Withdrawn prior to enrolment
Phase of Trial: Phase I
Latest Information Update: 25 Mar 2015
At a glance
- Drugs Fondaparinux sodium (Primary)
- Indications Ovarian cancer
- Focus Adverse reactions
- 23 Oct 2009 Status changed from recruiting to withdrawn prior to recruitment as reported by ClinicalTrials.gov.
- 06 May 2008 New trial record.